Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age50+
SponsorEyconis INC.
About this trial
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Eligibility criteria
Qualifiers
Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
Willing and able to comply with clinic visits and study-related procedures
Provide signed informed consent
Disqualifiers
Known hypersensitivity or known allergy that would preclude study drug administration
Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access
Uncontrolled diabetes mellitus
History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit
Trial design
Treatments tested in this trial
- EYC-0305
Treatment groups
30 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov